Emyria Ltd (AU:EMD) has released an update.
Emyria Limited has announced encouraging results from their MDMA-assisted therapy program for PTSD, showing substantial improvements in symptoms and quality of life for patients with moderate to severe PTSD. All patients from the initial cohort experienced clinically significant relief, with an average 33-point reduction in PTSD symptom scores and notable gains in quality of life. The company is expanding access to its innovative treatment, aiming to meet the needs of a broader patient population and reinforcing its position in the mental health treatment space.
For further insights into AU:EMD stock, check out TipRanks’ Stock Analysis page.
